The findings of Mooslechner et al., which showed the improvement of nephropathy with low-dose IL-15 treatment, may be instructive in defining the range over which recombinant IL-15 and IL-15 superagonists may be beneficial [117]. Here, IL15 is linked to kidney disorder.